Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Repeat infusions of CD19 CAR-T

Jordan Gauthier • 30 Mar 2020
Acute Lymphoblastic Leukemia Chronic Lymphocytic Leukemia Diffuse Large B-Cell Lymphoma Leukemia Lymphoma Cyclophosphamide Fludarabine

Jordan Gauthier, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, talks on the deepening of responses in patients previously treated with CD19 CAR-T cells by using repeated infusions of the cellular therapy. Dr Gauthier goes on to outline how the use of fully humanized CAR-T cells may reduce immunogenicity. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jordan Gauthier

3:40
Relationship between IL-15 serum concentrations & CD19 CAR T-cell therapy
Jordan Gauthier • 28 Jan 2021
3:23
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies
Jordan Gauthier • 28 Jan 2021
1:46
IACH webinar: continuing the CAR-T discussion amid COVID-19
Jordan Gauthier • 30 Mar 2020
3:50
CLL outcomes after CD19 CAR-T with ibrutinib
Jordan Gauthier • 30 Mar 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals